Bobica Alexandra Carla, Zhu Catherine, Silotch Catherine, BinJadeed Hessah, Netchiporouk Elena
Division of Clinical and Translational Research, McGill University, Montreal, QC, Canada.
Faculty of Medicine, McGill University, Montreal, QC, Canada.
SAGE Open Med Case Rep. 2025 May 14;13:2050313X251341561. doi: 10.1177/2050313X251341561. eCollection 2025.
We report the first documented use of brodalumab, an IL-17 receptor antagonist, for treating severe linear localized scleroderma refractory to conventional therapies, including methotrexate, mycophenolate mofetil and corticosteroids. The patient demonstrated rapid and sustained improvement in disease activity and severity, highlighting the potential role of IL-17 signaling in the pathogenesis of localized scleroderma. This case supports further investigation of IL-17 pathway blockade in autoimmune fibrotic diseases.
我们报告了首例有记录使用的抗白细胞介素-17（IL-17）受体拮抗剂布罗达单抗治疗对包括甲氨蝶呤、霉酚酸酯和皮质类固醇在内的传统疗法难治的重度线状局限性硬皮病。该患者的疾病活动度和严重程度迅速且持续改善，突出了IL-17信号传导在局限性硬皮病发病机制中的潜在作用。此病例支持进一步研究在自身免疫性纤维化疾病中阻断IL-17通路。
